Morningstar aktierapport

三生制药 01530

Seneste
6,35
Kursændring
-0,12|-1,85%

Data opdateret pr. 17-05-2024
16:08:16 HKT | HKD  Minimum 15 minutters forsinkelse.

Bud/UdbudDagens kursspændOmsætning3mGnsOmsMarkedsværdi
6,35 - 6,366,32 - 6,6115.222.20418.100.66015,23Mia.
Seneste luk52 ugers spændP/EUdbytteISIN
6,474,91 - 8,099,661,55KYG8875G1029
Mr. Lee Davidson, Head of Quantitative Research
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
Regnskaber
202120222023
Mere
Resultatopgørelse
Omsætning6.382,016.859,437.815,94
Resultat før skat1.881,422.079,572.458,37
Årets resultat1.651,251.914,891.549,24
Årets resultat pr. aktie0,650,780,64
Gns. aktiekapital - udvandet2.7702.6482.442
Balance
Omsætningsaktiver 7.790,709.760,939.192,68
Anlægsaktiver11.421,8812.227,7814.432,35
Aktiver i alt19.212,5821.988,7023.625,03
Kortfristet gæld1.419,991.793,933.727,61
Forpligtelser i alt---
Egenkapital12.227,4512.962,6714.033,77
Pengestrømsopgørelse
Pengestrømme fra driften1.578,352.180,282.082,86
Anlægsinvesteringer-1.145,77-973,73-704,34
Frie pengestrømme432,571.206,541.378,52

I mio., undtagen årets resultat pr. aktie. Valuta er CNY.

Profil

3SBio Inc, or 3SBio is a biotechnology company. As a pioneer in the Chinese biotechnology industry, the Group has extensive expertise in researching, developing, manufacturing, and marketing biopharmaceuticals. The core products of the Group include several biopharmaceutical drugs, TPIAO recombinant human erythropoietin rhEPO products EPIAO and SEPO, Yisaipu, Cipterbin, and a small molecule drug, Mandi. Except for minoxidil, an over-the-counter drug, the others are all older-generation biologics. The majority of its pipeline candidates are "me-too" drugs and in general, are still at an early stage.
Nøgletal
Mere
P/E - Kurs/indtjening (sidste 12m)-
P/B - Kurs/indre værdi1,02
P/S - Kurs/omsætning (sidste 12m)-
Omsætningsvækst (3 års gns)11,84
Vækst i indtj. pr. aktie (3 års gns)-
Indtjeningsgrad i % (sidste 12m)31,45
Overskudsgrad i % (sidste 12m)19,82
Egenkapitalforrentning (sidste 12m)11,48
Gæld/egenkapital0,19
Udbytte
ForrigeSeneste
Erklæringsdato21-03-2320-03-24
Ex. udbyttedato27-06-2322-07-24
Udbetalingsdato11-07-2305-08-24
Udbytte pr. aktie0,100,25
© Copyright 2024 Morningstar, Inc. All rights reserved.

Brugervilkår        Fortrolighedspolitik        Cookie Settings        Offentliggørelser